Skip to content
Adrienne Monson – Lifestyle
Author:
T-Therapeutics
T-Therapeutics announces oversubscribed $133 million Series B financing to achieve clinical proof-of-concept for first-in-class TCR bispecific therapies in cancer and autoimmune disease
November 5, 2026